LUNG CANCER

Dr Ticiana Leal, MD, discusses the role of topotecan and lurbinectedin as novel agents in second-line therapy for small cell lung cancer.

Dr Ticiana Leal, MD, lists the treatment options associated with first-line therapy and its relation to platinum sensitivity.

Dr Ticiana Leal, MD, comments on the treatment given, the effectiveness of treatment, and the future prognosis of this patient with small cell lung cancer.

Dr Ticiana Leal, MD, outlines the specific demographic and diagnosis of a patient with small cell lung cancer.

Ticiana Leal, MD, presents a case of a 61-year-old man with small cell lung cancer.

Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.

The emergence of tyrosine kinase inhibitors in early-stage disease is a late practice-changing development, said Roger C. Lilenbaum, MD.

Treatment with lurbinectedin and doxorubicin missed the prespecified end point of overall survival in patients with small cell lung cancer who progressed after 1 prior platinum therapy.

The FDA has granted a Fast Track designation to the irinotecan liposome injection as a potential treatment option for patients with small cell lung cancer who progressed following a first-line platinum-based regimen, Ipsen announced, in a press release.

The results from the phase 3 CASPIAN trial were reviewed and compared with the phase 3 IMpower133 by Jyoti D. Patel, MD, during a Targeted Oncology Case Based Peer Perspectives event.

Alexander Spira, MD, PhD, shares an important message with community oncologists regarding the treatment of patients with lung cancer.

During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.

The FDA has approved an additional dosing option for the approved indications of durvalumab at a 1500-mg fixed dose administered every 4 weeks.

During Lung Cancer Awareness Month, David Spigel, MD, shared his insights on the evolving treatment paradigm in lung cancer and how the latest advances have impacted his treatment decisions for patients with lung cancer.

Patients of color who were diagnosed with lung cancer were associated with worse outcomes compared with Caucasian patients, according to findings from the 3rd Annual “State of Lung Cancer” Report by the American Lung Association.

The primary end point of overall survival with tislelizumab compared with docetaxel as the second- or third-line treatment of patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.

Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.

The phase 3 KEYNOTE-598 study of pembrolizumab plus ipilimumab in a population of patients with metastatic non–small cell lung cancer has been discontinued for futility.

Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.